Medicines prices in International (Geary–Khamis) Dollar. The comparison between regulated and deregulated markets.

Autor: Zaprutko, Tomasz¹ (AUTHOR) tomekzaprutko@ump.edu.pl, Cynar, Julia² (AUTHOR), Sygit, Maria² (AUTHOR), Stolecka, Aleksandra² (AUTHOR), Skorupska, Patrycja² (AUTHOR), Jaszcz, Paulina² (AUTHOR), Kopciuch, Dorota¹ (AUTHOR), Paczkowska, Anna¹ (AUTHOR), Ratajczak, Piotr¹ (AUTHOR), Kus, Krzysztof¹ (AUTHOR)

Publikováno v: PLoS ONE. 6/7/2024, Vol. 19 Issue 6, p1-10. 10p.

Can Price Transparency Contribute to More Affordable Patient Access to Medicines?

Autor: Vogler S; WHO Collaborating Centre for Pharmaceutical Pricing and Reimbursement Policies, Pharmacoeconomics Department, Gesundheit Österreich GmbH (GÖG/Austrian Public Health Institute), Vienna, Austria. sabine.vogler@goeg.at., Paterson KR; University of Glasgow, Glasgow, Scotland, UK.

Publikováno v: PharmacoEconomics - open [Pharmacoecon Open] 2017 Sep; Vol. 1 (3), pp. 145-147.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Rapid Health Technology Assessment Of New Medicines: Lessons From 15 Years Experience In Scotland.

Autor: Paterson KR; University of Glasgow, Glasgow, United Kingdom.

Publikováno v: Clinical therapeutics [Clin Ther] 2016 Oct 06; Vol. 38 (10S), pp. e13.

How do people with diabetes access information?

Autor: Robertson, JL, Akhtar, S, Petrie, JR, Brown, FJ, Jones, GC, Perry, CG, Paterson, KR

Publikováno v: Practical Diabetes International; Jul2005, Vol. 22 Issue 6, p207-210, 7p